Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.15036/arerugi.73.1133 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epicutaneous immunotherapy for food allergy: a systematic review and meta-analysis.
Syst Rev
January 2025
Department of Pediatric, Affiliated Chifeng Clinical College of Inner, Mongolia Medical University, Chifeng, China.
Background: There is ongoing debate about the safety and efficacy of epicutaneous immunotherapy (EPIT) in treating food allergies. The systematic review and meta-analysis aimed to evaluate the safety and efficacy of EPIT.
Methods: We systematically searched international trial registers (ClinicalTrials.
Survey on Treatment-Seeking Patterns in Patients With Allergic Rhinitis.
J Rhinol
November 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Article Synopsis
- This study examined how patients with allergic rhinitis choose their treatments, including medications, environmental controls, and surgical options.
- Among 51 surveyed patients, most were prescribed medication, often only using it during symptoms, and many were aware of immunotherapy with no strong preference between types.
- A significant portion of patients reported using air purifiers for relief, but results varied on effectiveness, while those who underwent surgical treatment generally expressed high satisfaction levels.
Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan.
Allergy Asthma Proc
January 2025
Department of Pharmacovigilance, Pharmacovigilance and Quality Assurance Group, Torii Pharmaceutical Co., Ltd., Tokyo, Japan.
Standardized quality (SQ) house-dust mite (HDM) sublingual immunotherapy tablets (10,000 Japanese allergy units [JAU], equivalent to 6 SQ-HDM in Europe and the United States) are licensed for the treatment of HDM-induced allergic rhinitis (AR) without age restriction, based on 52-week administration clinical trials. There are no large-scale data on the administration of 10,000 JAU for > 1 year in actual clinical practice. To examine the safety and effectiveness of 10,000 JAU during use for up to 3 years at real-world clinical sites in Japan.
View Article and Find Full Text PDFAllergen immunotherapy: How to stay current with USP 797 and practice guidelines.
Allergy Asthma Proc
January 2025
The United States Pharmacopeia (USP) Chapter 797 provides critical standards for compounding sterile preparations to ensure patient safety and medication efficacy. The latest revision, effective November 1, 2023, introduces updates particularly relevant to the compounding of allergenic extracts, which emphasizes stringent compliance measures. This article aims to review the key updates to USP Chapter 797, outline the compliance requirements for personnel and facilities, and offer strategies for staying current with these practice guidelines, leveraging resources from professional organizations such as American College of Allergy, Asthma, and Immunology and American Academy of Allergy, Asthma, and Immunology.
View Article and Find Full Text PDFAtopic dermatitis (AD), a common chronic inflammatory skin disorder is characterized by a complex pathology with skin-barrier abnormalities, immune dysregulation, and microbial dysbiosis. Patients' quality of life is often negatively impacted by persistent pruritus, sleep disturbance, and recurrent skin infections. In addition, patients may have comorbid atopic as well as nonatopic diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!